NASDAQ:GILD - Gilead Sciences News Headlines

Sign in or create an account to add this stock to your watchlist.
$67.68 -0.33 (-0.49 %)
(As of 11/20/2018 10:35 AM ET)
Previous Close$68.01
Today's Range$67.6001 - $69.46
52-Week Range$64.27 - $89.54
Volume1.58 million shs
Average Volume7.46 million shs
Market Capitalization$89.52 billion
P/E Ratio7.91
Dividend Yield3.29%
Beta1.01

Headlines

Gilead Sciences (NASDAQ GILD) News Headlines

Source:
DateHeadline
Gilead Sciences (GILD) Receiving Somewhat Negative Press Coverage, Study FindsGilead Sciences (GILD) Receiving Somewhat Negative Press Coverage, Study Finds
www.americanbankingnews.com - November 20 at 7:26 AM
Gilead’s Vemlidy for chronic hepatitis B virus approved in ChinaGilead’s Vemlidy for chronic hepatitis B virus approved in China
seekingalpha.com - November 19 at 3:01 PM
China National Medical Products Administration (NMPA) Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for Chronic Hepatitis B Virus (HBV) InfectionChina National Medical Products Administration (NMPA) Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for Chronic Hepatitis B Virus (HBV) Infection
finance.yahoo.com - November 19 at 5:03 AM
Gilead Sciences (GILD) "Hold" Rating Reiterated at OppenheimerGilead Sciences' (GILD) "Hold" Rating Reiterated at Oppenheimer
www.americanbankingnews.com - November 15 at 3:26 PM
Gilead Sciences (GILD) Stock Rating Reaffirmed by Needham & Company LLCGilead Sciences (GILD) Stock Rating Reaffirmed by Needham & Company LLC
www.americanbankingnews.com - November 14 at 4:28 PM
Gilead Sciences to Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27Gilead Sciences to Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27
finance.yahoo.com - November 13 at 5:07 AM
Gilead Sciences, Inc. (GILD) Expected to Announce Quarterly Sales of $5.52 BillionGilead Sciences, Inc. (GILD) Expected to Announce Quarterly Sales of $5.52 Billion
www.americanbankingnews.com - November 13 at 2:30 AM
Gilead Sciences, Inc. (GILD) Expected to Post Earnings of $1.74 Per ShareGilead Sciences, Inc. (GILD) Expected to Post Earnings of $1.74 Per Share
www.americanbankingnews.com - November 11 at 5:22 PM
Somewhat Positive Press Coverage Very Likely to Affect Gilead Sciences (GILD) Stock PriceSomewhat Positive Press Coverage Very Likely to Affect Gilead Sciences (GILD) Stock Price
www.americanbankingnews.com - November 10 at 7:54 PM
Gilead Sciences (GILD) Presents Latest Data from Viral Hepatitis Research Programs at The Liver MeetingGilead Sciences (GILD) Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting
www.streetinsider.com - November 10 at 5:15 AM
Gilead Sciences (GILD) Announces Positive Phase 2 Results for GS-9674 in Primary PSC at The Liver MeetingGilead Sciences (GILD) Announces Positive Phase 2 Results for GS-9674 in Primary PSC at The Liver Meeting
www.streetinsider.com - November 10 at 5:15 AM
Gileads GS-9674 shows positive action in mid-stage NASH studyGilead's GS-9674 shows positive action in mid-stage NASH study
seekingalpha.com - November 9 at 3:14 PM
Gilead Presents Data From Nonalcoholic Steatohepatitis (NASH) Development Program for Advanced Fibrosis at The Liver Meeting® 2018Gilead Presents Data From Nonalcoholic Steatohepatitis (NASH) Development Program for Advanced Fibrosis at The Liver Meeting® 2018
finance.yahoo.com - November 9 at 3:14 PM
Gilead Announces Positive Phase 2 Results for GS-9674 in Primary Sclerosing Cholangitis (PSC) at The Liver Meeting® 2018Gilead Announces Positive Phase 2 Results for GS-9674 in Primary Sclerosing Cholangitis (PSC) at The Liver Meeting® 2018
finance.yahoo.com - November 9 at 3:14 PM
Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting® 2018Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting® 2018
finance.yahoo.com - November 9 at 3:14 PM
Is Gilead Sciences Inc’s (NASDAQ:GILD) Balance Sheet Strong Enough To Weather A Storm?Is Gilead Sciences Inc’s (NASDAQ:GILD) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - November 8 at 3:18 PM
Biotech Analysis Central Pharma News: Gileads Push, AcelRxs Approval, Trevenas RejectionBiotech Analysis Central Pharma News: Gilead's Push, AcelRx's Approval, Trevena's Rejection
seekingalpha.com - November 7 at 3:15 PM
Exclusive: Small Peninsula city rejects developer's housing plan — and tells it to go biggerExclusive: Small Peninsula city rejects developer's housing plan — and tells it to go bigger
finance.yahoo.com - November 6 at 5:00 AM
John C. Martin Sells 50,000 Shares of Gilead Sciences, Inc. (GILD) StockJohn C. Martin Sells 50,000 Shares of Gilead Sciences, Inc. (GILD) Stock
www.americanbankingnews.com - November 5 at 10:14 PM
Why Gilead Sciences, Inc. Stock Broke Down in OctoberWhy Gilead Sciences, Inc. Stock Broke Down in October
www.fool.com - November 5 at 11:55 AM
Gilead Sciences (GILD) Earning Somewhat Favorable Media Coverage, Analysis FindsGilead Sciences (GILD) Earning Somewhat Favorable Media Coverage, Analysis Finds
www.americanbankingnews.com - November 5 at 3:12 AM
Gilead Sciences’ Operational PerformanceGilead Sciences’ Operational Performance
finance.yahoo.com - November 2 at 3:06 PM
What Does Gilead Sciences’ Bottom-Line Trend Indicate?What Does Gilead Sciences’ Bottom-Line Trend Indicate?
finance.yahoo.com - November 2 at 3:06 PM
Gilead Sciences: An Update for InvestorsGilead Sciences: An Update for Investors
finance.yahoo.com - November 2 at 3:06 PM
Gilead Stock to Jump Double Digits: Morgan StanleyGilead Stock to Jump Double Digits: Morgan Stanley
finance.yahoo.com - November 2 at 3:06 PM
Gilead Sciences Is Sporting a Bearish Set of Charts for InvestorsGilead Sciences Is Sporting a Bearish Set of Charts for Investors
finance.yahoo.com - November 2 at 3:06 PM
Decatur-based task force becoming ground zero for global elimination of hepatitis B and CDecatur-based task force becoming ground zero for global elimination of hepatitis B and C
finance.yahoo.com - November 2 at 5:07 AM
Raymond James Reaffirms Buy Rating for Gilead Sciences (GILD)Raymond James Reaffirms Buy Rating for Gilead Sciences (GILD)
www.americanbankingnews.com - November 1 at 1:22 PM
Gilead Sciences (GILD) Given a $94.00 Price Target by Mizuho AnalystsGilead Sciences (GILD) Given a $94.00 Price Target by Mizuho Analysts
www.americanbankingnews.com - November 1 at 9:39 AM
Investor Expectations to Drive Momentum within Gilead Sciences, SCANA, Brinks, Fortive, Asbury Automotive Group ...Investor Expectations to Drive Momentum within Gilead Sciences, SCANA, Brink's, Fortive, Asbury Automotive Group ...
globenewswire.com - November 1 at 5:08 AM
Gilead Remains A SellGilead Remains A Sell
seekingalpha.com - November 1 at 5:08 AM
Jerome Dodson Comments on Gilead SciencesJerome Dodson Comments on Gilead Sciences
finance.yahoo.com - November 1 at 5:08 AM
Gilead Sciences (GILD) "Buy" Rating Reaffirmed at Evercore ISIGilead Sciences' (GILD) "Buy" Rating Reaffirmed at Evercore ISI
www.americanbankingnews.com - October 31 at 3:27 PM
SPTM, TXN, GILD, LMT: Large Inflows Detected at ETFSPTM, TXN, GILD, LMT: Large Inflows Detected at ETF
www.nasdaq.com - October 31 at 3:09 PM
Gilead teams up with Tango Therapeutics in cancerGilead teams up with Tango Therapeutics in cancer
seekingalpha.com - October 31 at 3:09 PM
Gilead down 6% as investors unmoved with Tango dealGilead down 6% as investors unmoved with Tango deal
seekingalpha.com - October 31 at 3:09 PM
Gilead shares drop after new UnitedHealth program incentivizes cheaper HIV medsGilead shares drop after new UnitedHealth program incentivizes cheaper HIV meds
finance.yahoo.com - October 31 at 3:09 PM
Gileads Biktarvy on par with DTG+FTC/TAF in late-stage HIV studyGilead's Biktarvy on par with DTG+FTC/TAF in late-stage HIV study
seekingalpha.com - October 30 at 3:06 PM
Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV TherapyGilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy
finance.yahoo.com - October 30 at 3:06 PM
Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q2Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q2
finance.yahoo.com - October 29 at 3:01 PM
Gilead: More Of The SameGilead: More Of The Same
seekingalpha.com - October 29 at 9:35 AM
How Did Gilead Sciences Fare in the Third Quarter?How Did Gilead Sciences Fare in the Third Quarter?
finance.yahoo.com - October 29 at 9:35 AM
Gilead Sciences, Inc. (GILD) Given Average Recommendation of "Buy" by AnalystsGilead Sciences, Inc. (GILD) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - October 28 at 12:30 PM
Critical Survey: Gilead Sciences (GILD) vs. Solid Biosciences (SLDB)Critical Survey: Gilead Sciences (GILD) vs. Solid Biosciences (SLDB)
www.americanbankingnews.com - October 27 at 12:10 PM
Gilead Sciences, Inc. (GILD) Short Interest UpdateGilead Sciences, Inc. (GILD) Short Interest Update
www.americanbankingnews.com - October 27 at 2:38 AM
Mizuho Reiterates $94.00 Price Target for Gilead Sciences (GILD)Mizuho Reiterates $94.00 Price Target for Gilead Sciences (GILD)
www.americanbankingnews.com - October 26 at 7:04 PM
Gilead Sciences (GILD) PT Raised to $95.00 at BarclaysGilead Sciences (GILD) PT Raised to $95.00 at Barclays
www.americanbankingnews.com - October 26 at 4:55 PM
Gilead Sciences Stock Is Back to Base — Go LongGilead Sciences Stock Is Back to Base — Go Long
investorplace.com - October 26 at 4:49 PM
Gilead Sciences (GILD) Price Target Cut to $94.00 by Analysts at Raymond JamesGilead Sciences (GILD) Price Target Cut to $94.00 by Analysts at Raymond James
www.americanbankingnews.com - October 26 at 4:31 PM
Amazon Tumbles, Gilead Slumps as S&P 500 Eyes CorrectionAmazon Tumbles, Gilead Slumps as S&P 500 Eyes Correction
www.barrons.com - October 26 at 3:09 PM
This page was last updated on 11/20/2018 by MarketBeat.com Staff

Featured Article: What is Depreciation?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel